Latest ORBIMED ADVISORS LLC Stock Portfolio

ORBIMED ADVISORS LLC Performance:

2025 Q4: 20.71%YTD: 19.31%2024: 9.44%

Performance for 2025 Q4 is 20.71%, and YTD is 19.31%, and 2024 is 9.44%.

About ORBIMED ADVISORS LLC and 13F Hedge Fund Stock Holdings

ORBIMED ADVISORS LLC is a hedge fund based in New York, NY. On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, ORBIMED ADVISORS LLC reported an equity portfolio of $4.9 Billions as of 31 Dec, 2025.

The top stock holdings of ORBIMED ADVISORS LLC are EWTX, LLY, BSX. The fund has invested 7.9% of it's portfolio in EDGEWISE THERAPEUTICS INC and 6.6% of portfolio in ELI LILLY & CO.

The fund managers got completely rid off SI-BONE INC (SIBN), SCPHARMACEUTICALS INC (SCPH) and INTEGER HLDGS CORP (ITGR) stocks. They significantly reduced their stock positions in CULLINAN THERAPEUTICS INC (CGEM), C4 THERAPEUTICS INC (CCCC) and TERNS PHARMACEUTICALS INC (TERN). ORBIMED ADVISORS LLC opened new stock positions in BRISTOL-MYERS SQUIBB CO (BMY), PFIZER INC (PFE) and ELEVANCE HEALTH INC FORMERLY (ANTX). The fund showed a lot of confidence in some stocks as they added substantially to MIND MEDICINE MINDMED INC (MNMD), BIOCRYST PHARMACEUTICALS INC (BCRX) and INSMED INC (INSM).

ORBIMED ADVISORS LLC Annual Return Estimates Vs S&P 500

Our best estimate is that ORBIMED ADVISORS LLC made a return of 20.71% in the last quarter. In trailing 12 months, it's portfolio return was 19.31%.

Performance
S&P 500

New Buys

Ticker	$ Bought
bristol-myers squibb co	41,803,500
pfizer inc	41,157,200
elevance health inc formerly	34,739,500
cybin inc	31,415,300
praxis precision medicines i	27,852,900
bruker corp	26,183,200
esperion therapeutics inc ne	22,072,300
lexeo therapeutics inc	21,101,200

New stocks bought by ORBIMED ADVISORS LLC

Additions

Ticker	% Inc.
mind medicine mindmed inc	233
biocryst pharmaceuticals inc	93.21
insmed inc	88.72
brightspring health svcs inc	85.18
uniqure nv	60.83
rapt therapeutics inc	51.19
inspiremd inc	46.87
eyepoint inc	37.43

Additions to existing portfolio by ORBIMED ADVISORS LLC

Reductions

Ticker	% Reduced
cullinan therapeutics inc	-85.97
c4 therapeutics inc	-73.16
terns pharmaceuticals inc	-71.53
exact sciences corp	-64.64
avidity biosciences inc	-62.2
cytomx therapeutics inc	-58.33
amicus therapeutics inc	-55.64
axsome therapeutics inc	-52.4

ORBIMED ADVISORS LLC reduced stake in above stock

Sold off

Ticker	$ Sold
scpharmaceuticals inc	-34,357,500
milestone pharmaceuticals in	-6,443,660
si-bone inc	-37,962,600
celcuity inc	-2,684,240
dih hldg us inc	-358,105
verastem inc	-7,837,160
amylyx pharmaceuticals inc	-10,200,700
adicet bio inc	-9,274,470

ORBIMED ADVISORS LLC got rid off the above stocks

Sector Distribution

ORBIMED ADVISORS LLC has about 66.5% of it's holdings in Healthcare sector.

Sector	%
Healthcare	66.5
Others	31.5
	2

Market Cap. Distribution

ORBIMED ADVISORS LLC has about 33.7% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
UNALLOCATED	31.5
LARGE-CAP	26.9
MID-CAP	17.7
SMALL-CAP	13.4
MEGA-CAP	6.8
MICRO-CAP	2.9

Stocks belong to which Index?

About 49.4% of the stocks held by ORBIMED ADVISORS LLC either belong to S&P 500 or RUSSELL 2000 index.

Index	%
Others	50.6
S&P 500	24.8
RUSSELL 2000	24.6

Top 5 Winners (%)		%
TERN	terns pharmaceuticals inc	281.3 %
	alto neuroscience inc	257.1 %
	structure therapeutics inc	144.9 %
	bioage labs inc	125.0 %
	alumis inc	113.7 %

Top 5 Winners ($)		$
TERN	terns pharmaceuticals inc	159.8 M
EWTX	edgewise therapeutics inc	133.4 M
LLY	eli lilly & co	93.9 M
	mbx biosciences inc	55.7 M
	structure therapeutics inc	47.8 M

Top 5 Losers (%)		%
VSTA	vistagen therapeutics inc	-81.3 %
QURE	uniqure nv	-53.9 %
JANX	janux therapeutics inc	-42.3 %
ONTX	traws pharma inc	-38.9 %
CRBP	corbus pharmaceuticals hldgs	-32.5 %

Top 5 Losers ($)		$
	enliven therapeutics inc	-40.4 M
QURE	uniqure nv	-20.6 M
JANX	janux therapeutics inc	-19.8 M
ALNY	alnylam pharmaceuticals inc	-17.2 M
ORIC	oric pharmaceuticals inc	-13.9 M

ORBIMED ADVISORS LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of ORBIMED ADVISORS LLC

ORBIMED ADVISORS LLC has 104 stocks in it's portfolio. About 40.4% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. TERN was the most profitable stock for ORBIMED ADVISORS LLC last quarter.

Last Reported on: 17 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
AADI	whitehawk therapeutics inc	0.21	4,166,000	10,081,700	unchanged	0.00

ACET	adicet bio inc	0.18	1,027,940	8,655,290	new

ACET	adicet bio inc	0.00	0.00	0.00	sold off	-100

ADCT	adc therapeutics sa	0.42	5,822,850	20,554,700	reduced	-1.43

AKRO	akero therapeutics inc	0.00	0.00	0.00	sold off	-100

ALNY	alnylam pharmaceuticals inc	2.34	288,800	114,841,000	reduced	-4.24

AMLX	amylyx pharmaceuticals inc	0.00	0.00	0.00	sold off	-100

ANTX	elevance health inc formerly	0.71	99,100	34,739,500	new

APLS	apellis pharmaceuticals inc	1.25	2,429,870	61,038,300	added	4.58

ARGX	argenx se	2.51	146,000	122,779,000	reduced	-15.26

ASND	ascendis pharma a/s	0.75	171,977	36,672,400	reduced	-10.38

ATAI	atai life sciences nv	0.00	0.00	0.00	sold off	-100

AVTE	jade biosciences inc	0.17	531,163	8,195,840	unchanged	0.00

AVTX	avalo therapeutics inc	0.44	1,187,300	21,561,400	reduced	-12.01

AXSM	axsome therapeutics inc	0.94	253,121	46,230,000	reduced	-52.4

BCRX	biocryst pharmaceuticals inc	0.28	1,741,800	13,586,000	added	93.21

BMY	bristol-myers squibb co	0.85	775,000	41,803,500	new

BRKR	bruker corp	0.53	555,789	26,183,200	new

BSX	boston scientific corp	4.71	2,419,300	230,680,000	reduced	-0.41

CCCC	c4 therapeutics inc	0.06	1,404,900	2,683,360	reduced	-73.16